Relmacabtagene autoleucel Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Relmacabtagene autoleucel Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Relmacabtagene autoleucel can convert its Autologous CAR-T profile and CD19 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Relmacabtagene autoleucel (query alias: Relmacabtagene autoleucel) |
|---|---|
| Modality / target | Autologous CAR-T; CD19; CD19 inhibitors |
| Highest global status | Approved |
| Originator | JW Therapeutics (Shanghai) Co., Ltd. |
| Active developers | JW Therapeutics (Shanghai) Co., Ltd., Ruijin Hospital, Shanghai Ming Ju Biotechnology Co. Ltd. |
The MCP disease footprint includes Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma, Mantle cell lymphoma recurrent. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07077512 | Phase 2 | Recruiting | 30 | The complete response rate (CRR) at 3 months |
| NCT06876688 | Phase 2 | Recruiting | 30 | Complete response rate(CRR) at 3-month |
| NCT07326371 | Phase 2 | Not yet recruiting | 24 | Complete Response Rate (CRR) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
国家药品监督管理局已正式接受Carteyva®上市后补充申请，该药物采用公司自主研发的慢病毒载体
临床2期; n=not disclosed; evaluation: 积极. Reported fields: ORR(3-month, best) = 66.67 %
Phase 2 Study of Relmacabtagene Autoleucel (CD19 CAR-T) for Relapsed/Refractory Mantle Cell Lymphoma in Chinese Adults
Phase 2; n=70; evaluation: Positive. Reported fields: ORR(3 months) = 71.19 % (95%CI, 57.92 - 82.24)
RELMACABTAGENE AUTOLEUCEL (RELMA-CEL) AS SECOND-LINE THERAPY FOR R/R AGGRESSIVE B-NHL IN PATIENTS INELIGIBLE FOR HDCT/ASCT: PRIMARY ANALYSIS FROM A PHASE 2 STUDY
Phase 2; n=53; evaluation: Positive. Reported fields: -; Investigator-assessed best ORR = 81.3 % ( 67.4 - 91.1)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Relmacabtagene autoleucel addresses Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma, Mantle cell lymphoma recurrent. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Autologous CAR-T—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 144 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: CD19 records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-07-21 | Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T | Preclinical | Financial terms not disclosed |
| 2026-06-02 | Cencora to Support U.S. Distribution of Kite’s CAR T-Cell Therapies | Approved | Financial terms not disclosed |
| 2026-05-21 | Struggling Liminatus pays $320M in stock for CAR-T biotech InnocsAI | Preclinical | US$320.0M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 23 July 2026. Counts and status fields may change as source records update.
